A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial

Elizabeth Littlewood,1 Ana Duarte,2 Catherine Hewitt,3 Sarah Knowles,4,5 Stephen Palmer,2 Simon Walker,2 Phil Andersen,1 Ricardo Araya,6,7 Michael Barkham,8 Peter Bower,5 Sally Brabyn,1 Gwen Brierley,1,9 Cindy Cooper,10 Linda Gask,5 David Kessler,11 Helen Lester,5,12† Karina Lovell,13 Usman Muhammad,3 Glenys Parry,10 David A Richards,1,14 Rachel Richardson,1 Debbie Tallon,15 Puvan Tharmanathan,3 David White10 and Simon Gilbody1* on behalf of the REEACT Team

1Department of Health Sciences, University of York, York, UK
2Centre for Health Economics, University of York, York, UK
3York Trials Unit, Department of Health Sciences, University of York, York, UK
4Centre for Primary Care, Institute of Population Health, University of Manchester, Manchester, UK
5National Institute for Health Research (NIHR) School for Primary Care Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK (previously National Primary Care Research and Development Centre, University of Manchester, Manchester, UK)
6Academic Unit of Psychiatry, University of Bristol, Bristol, UK
7Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK
8Centre for Psychological Services Research, University of Sheffield, Sheffield, UK
9Medical Research Council (MRC) Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK
10Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK
11Academic Unit of Primary Health Care, University of Bristol, Bristol, UK
12Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
13School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK
14University of Exeter Medical School, University of Exeter, Exeter, UK
15School of Social & Community Medicine, University of Bristol, Bristol, UK

*Corresponding author
†In memoriam
Declared competing interests of authors: Simon Gilbody is a Health Technology Assessment Clinical Evaluation and Trials Board Member. Michael Barkham is a developer of the Clinical Outcomes in Routine Evaluation – Outcome Measure, which was used as a secondary outcome measure in the trial. Peter Bower reports personal fees from paid consultancy for the British Association of Counselling and Psychotherapy, outside the submitted work. Karina Lovell is a Non-Executive Director for Manchester Mental Health and Social Care Trust and is paid a salary.

Published December 2015
DOI: 10.3310/hta191010

Scientific summary
A RCT of cCBT for the treatment of depression in primary care
Health Technology Assessment 2015; Vol. 19: No. 101
DOI: 10.3310/hta191010

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Depression is the most common mental health disorder in community settings and is estimated to become the second largest cause of global disability by 2020. It is one of the most common reasons for consulting a general practitioner (GP) and is associated with significant personal and economic burden. Antidepressant medication is an important treatment option for depression; however, many patients and health-care professionals would like to access psychological therapy as an alternative or adjunct to medication. A leading evidence-supported form of brief psychological therapy for people with depression is cognitive behaviour therapy (CBT), but unfortunately patient demand for CBT cannot be met from existing therapist resources. There is a need to increase patient access to psychological therapy and one potential way of achieving this might be the provision of CBT delivered via computer. The provision of computerised CBT (cCBT) is recommended in the National Institute for Health and Care Excellence (NICE) guidelines as an initial lower-intensity treatment for depression as part of a ‘stepped care’ approach in primary care. Much of the existing evidence for the short-term clinical effectiveness of cCBT for depression comes from research conducted by the developers of the cCBT programs. Research conducted by independent researchers is needed to establish both the clinical effectiveness and the cost-effectiveness of cCBT in the short term and over the longer term. Whether or not free-to-use cCBT programs are as effective as commercial pay-to-use cCBT programs also needs to be determined. There is also a lack of research examining the acceptability of cCBT, both to patients and health professionals, as well as the issue of patient preference and its relationship to treatment uptake and effectiveness.

Objectives

The REEACT (Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy) trial was a randomised controlled trial (RCT) of usual GP care versus the addition of one of two cCBT programs for the treatment of depression in adults. This included concurrent qualitative and economic evaluations.

The specific objectives of the REEACT trial were:

1. to establish the clinical effectiveness and cost-effectiveness of cCBT in addition to usual GP care compared with usual GP care alone over a 2-year trial follow-up period
2. to establish the acceptability (to patients and health professionals) of cCBT
3. to establish the differential clinical effectiveness and cost-effectiveness of a free-to-use cCBT program (MoodGYM; National Institute for Mental Health Research, Australian National University, Canberra, Australia) in comparison with a commercial pay-to-use cCBT program (Beating the Blues®; Ultrasis, London, UK) over a 2-year and longer-term time horizon.

Method

Design

A pragmatic, multicentre, three-armed RCT with concurrent economic and qualitative evaluations. The design included a fully randomised patient preference approach. Participants were randomised using simple randomisation (1 : 1 : 1) with allocation concealed. Treatment allocation and outcome measurement were not concealed.
**Setting**
Participants were recruited from GP practices in Bristol, Manchester, Sheffield, York, Hull and the north-east of England.

**Participants**
Potential participants were identified (1) by direct referral by a GP or health professional attached to a GP practice or (2) following a written approach by the GP after identification via GP practice database screening. Potential participants were eligible to participate in the trial if they were aged 18 years and over, scored 10 or above on a validated depression severity instrument [Patient Health Questionnaire-9 (PHQ-9)] and were not in receipt of cCBT or specialist psychological therapy.

**Interventions**
Participants were randomised to receive: (1) a free-to-use cCBT program (MoodGYM) plus usual GP care; (2) a commercial pay-to-use cCBT program (Beating the Blues) plus usual GP care; or (3) usual GP care alone. Given the pragmatic design of the trial, no restrictions were imposed on the range of treatments that could be offered by a GP as part of usual care. Both intervention programs were based on CBT and both have been endorsed by NICE in the initial treatment of depression in primary care. The cCBT programs involved internet-based interactive therapy sessions, which could be accessed at the participant’s home, in a central location close to the participant’s home or at the GP practice, depending on patient preference and availability. Intervention participants received technical support and encouragement to complete the cCBT program via weekly telephone calls.

**Main outcome measures**
The primary outcome was self-reported symptoms of depression, assessed by the PHQ-9 at 4 months post randomisation. Secondary outcomes were: self-reported symptoms of depression (PHQ-9) at 12 and 24 months; global and generic measures of mental health, health-related quality of life and patient-level resource use, each at 4, 12 and 24 months; treatment preference; and participants’ and health professionals’ experiences of cCBT and perceptions of its acceptability.

**Results**

**Clinical effectiveness:** a total of 691 patients, aged 18–76 years, were recruited to the trial between August 2009 and March 2011, with 210 participants randomised to receive pay-to-use cCBT (Beating the Blues) plus usual GP care, 242 participants randomised to receive free-to-use cCBT (MoodGYM) plus usual GP care and 239 participants randomised to receive usual GP care alone. Analyses used intention-to-treat. There was no significant difference in depression at the primary outcome measured at 4 months for either Beating the Blues versus usual GP care alone [odds ratio (OR) 1.19, 95% confidence interval (CI) 0.75 to 1.88] or MoodGYM versus usual GP care alone (OR 0.98, 95% CI 0.62 to 1.56). There was no overall difference across all time points for either intervention compared with usual GP care alone in a mixed model (Beating the Blues vs. usual GP care alone, \( p = 0.96 \); and MoodGYM vs. usual GP care alone, \( p = 0.11 \)). However, a small, but statistically significant, difference between MoodGYM and usual GP care alone at 12 months was found (OR 0.56, 95% CI 0.34 to 0.93). In a non-inferiority analysis, free-to-use cCBT (MoodGYM) was not shown to be inferior to pay-to-use cCBT (Beating the Blues) (OR 0.91, 90% CI 0.62 to 1.34; \( p = 0.69 \)). There were no consistent benefits for either intervention when secondary outcomes were examined. Participants showed a preference for cCBT prior to randomisation; however, cCBT was equally ineffective for those with and without a strong preference. Despite the provision of regular telephone calls for technical support and encouragement, there was low uptake of the cCBT programs. There were no serious adverse events thought likely to be related to the trial intervention.

**Cost-effectiveness:** the trial-based cost-effectiveness analyses suggest that neither Beating the Blues nor MoodGYM was cost-effective compared with usual GP care alone. Beating the Blues was more expensive and resulted in fewer quality-adjusted life-years (QALYs) than usual GP care (dominated), and MoodGYM
resulted in fewer QALYs but at lower cost. Usual GP care alone compared with either cCBT intervention was also the cost-effective intervention in the majority of scenario analyses and was the intervention most likely to be cost-effective at a £20,000 per QALY threshold (probabilities ranging across scenarios from 0.545 to 0.619).

**Qualitative evaluation:** when exploring the reasons for poor engagement of the cCBT programs, it was found that depression often demotivated participants to access the computer programs in their own time and when left to their own devices. Some said that a greater level of therapeutic input would be needed to promote engagement. GPs did not believe that cCBT could be offered within primary care premises.

**Conclusions**

The benefits that have previously been observed in developer-led trials were not found in this large pragmatic RCT conducted in routine UK primary care services. The benefits of cCBT when added to routine primary care were minimal and there was relatively low uptake of this mode of therapy.

**Implications for health care**

- In this trial for patients with moderate or severe depression powered to detect non-inferiority, technically supported cCBT in addition to usual GP care was no more effective than usual GP care alone. Practice recommendations such as those offered by NICE and Improving Access to Psychological Therapies stepped models of care might usefully be re-examined in the light of these findings.
- We consider that, where cCBT continues to be offered within the portfolio of low-intensity psychological treatment, there should be early follow-up in primary care to identify patients for whom the intervention may be unsuitable.
- Commissioners of services should take note of our findings that commercially produced products may add little benefit to usual GP care.
- We found no substantial difference in outcomes between the commercially produced product (Beating the Blues), when offered in addition to usual GP care, and the free-to-use product (MoodGYM), which is clearly less costly for the NHS.
- Free-to-use products such as MoodGYM could be offered in response to patient choice. However, our overall finding of the relative lack of benefit of these programs in addition to usual GP care should also be taken into account in this context.

**Recommendations for future research**

There remains a clinical and economic need for effective low-intensity psychological treatments for depression. Trials of alternative low-intensity treatments such as telephone-guided bibliotherapy, telephone-guided self-help or more intensively guided cCBT are needed. All such studies should be framed in primary care and conducted by researchers other than product developers. In the longer term, if computers are to be used to deliver psychological treatment with minimal therapist input, then there needs to be improved patient experience and engagement through greater personalisation of treatment packages. This requires further research and innovation at the human–computer interface.

**Trial registration**

This trial is registered as ISRCTN91947481.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.116

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 06/43/05. The contractual start date was in May 2009. The draft report began editorial review in January 2014 and was accepted for publication in September 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Littlewood et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk